Trial Profile
A Phase 2, Multicenter Study With Open-Label and Randomized Double-Blind Placebo-Controlled Withdrawal Phases to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Who Are Clinically Stable and Taking Stable Doses of Atypical Antipsychotic Medication.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Shire
- 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
- 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
- 02 May 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.